A Novel Synthetic Simulation Platform for Validation of Breathing Rate Measurement

Surveillance of high-risk early postsurgical patients for real-time detection of complications using wireless monitoring (SHEPHERD study): results of a randomized multicenter stepped wedge cluster trial

Background

Vital signs measurements on the ward are performed intermittently. This could lead to failure to rapidly detect patients with deteriorating vital signs and worsens long-term outcome. The aim of this study was to test the hypothesis that continuous wireless monitoring of vital signs on the postsurgical ward improves patient outcome.

Methods

In this prospective, multicenter, stepped-wedge cluster randomized study, patients in the control group received standard monitoring. The intervention group received continuous wireless monitoring of heart rate, respiratory rate and temperature on top of standard care. Automated alerts indicating vital signs deviation from baseline were sent to ward nurses, triggering the calculation of a full early warning score followed. The primary outcome was the occurrence of new disability three months after surgery.

Results

The study was terminated early (at 57% inclusion) due to COVID-19 restrictions. Therefore, only descriptive statistics are presented. A total of 747 patients were enrolled in this study and eligible for statistical analyses, 517 patients in the control group and 230 patients in the intervention group, the latter only from one hospital. New disability at three months after surgery occurred in 43.7% in the control group and in 39.1% in the intervention group (absolute difference 4.6%).

Conclusion

This is the largest randomized controlled trial investigating continuous wireless monitoring in postoperative patients. While patients in the intervention group seemed to experience less (new) disability than patients in the control group, results remain inconclusive with regard to postoperative patient outcome due to premature study termination.

Clinical trial registration

ClinicalTrials.gov, ID: NCT02957825.

ECG Signal Quality Assessments of a Small Bipolar Single-Lead Wearable Patch Sensor

PURPOSE

There is an increasing clinical interest in the adoption of small single-lead wearable ECG sensors for continuous cardiac monitoring. The purpose of this work is to assess ECG signal quality of such devices compared to gold standard 12-lead ECG.

METHODS

The ECG signal from a 1-lead patch was systematically compared to the 12-lead ECG device in thirty subjects to establish its diagnostic accuracy in terms of clinically relevant signal morphology, wave representation, fiducial markers and interval and wave duration. One minute ECG segments with good signal quality was selected for analysis and the features of ECG were manually annotated for comparative assessment.

RESULTS

The patch showed closest similarity based on correlation and normalized root-mean-square error to the standard ECG leads I, II, [Formula: see text] and [Formula: see text]. P-wave and QRS complexes in the patch showed sensitivity (Se) and positive predictive value (PPV) of at least 99.8% compared to lead II. T-wave representation showed Se and PPV of at least 99.9% compared to lead [Formula: see text] and [Formula: see text]. Mean errors for onset and offset of the ECG waves, wave durations, and ECG intervals were within 2 samples based on 125Hz patch ECG sampling frequency.

CONCLUSION

This study demonstrates the diagnostic capability with similar morphological representation and reasonable timing accuracy of ECG signal from a patch sensor compared to 12-lead ECG. The advantages and limitations of small bipolar single-lead wearable patch sensor compared to 12-lead ECG are discussed in the context of relevant differences in ECG signal for clinical applications.

Continuous vital sign monitoring using a wearable patch sensor in obese patients: a validation study in a clinical setting

Our aim was to determine the agreement of heart rate (HR) and respiratory rate (RR) measurements by the Philips Biosensor with a reference monitor (General Electric Carescape B650) in severely obese patients during and after bariatric surgery. Additionally, sensor reliability was assessed. Ninety-four severely obese patients were monitored with both the Biosensor and reference monitor during and after bariatric surgery. Agreement was defined as the mean absolute difference between both monitoring devices. Bland Altman plots and Clarke Error Grid analysis (CEG) were used to visualise differences. Sensor reliability was reflected by the amount, duration and causes of data loss. The mean absolute difference for HR was 1.26 beats per minute (bpm) (SD 0.84) during surgery and 1.84 bpm (SD 1.22) during recovery, and never exceeded the 8 bpm limit of agreement. The mean absolute difference for RR was 1.78 breaths per minute (brpm) (SD 1.90) during surgery and 4.24 brpm (SD 2.75) during recovery. The Biosensor's RR measurements exceeded the 2 brpm limit of agreement in 58% of the compared measurements. Averaging 15 min of measurements for both devices improved agreement. CEG showed that 99% of averaged RR measurements resulted in adequate treatment. Data loss was limited to 4.5% of the total duration of measurements for RR. No clear causes for data loss were found. The Biosensor is suitable for remote monitoring of HR, but not RR in morbidly obese patients. Future research should focus on improving RR measurements, the interpretation of continuous data, and development of smart alarm systems.

Novel Continuous Respiratory Rate Monitoring Using an Armband Wearable Sensor

Photoplethysmography (PPG) and accelerometer (ACC) are commonly integrated into wearable devices for continuous unobtrusive pulse rate and activity monitoring of individuals during daily life. However, obtaining continuous and clinically accurate respiratory rate measurements using such wearable sensors remains a challenge. This article presents a novel algorithm for estimation of respiration rate (RR) using an upper-arm worn wearable device by deriving multiple respiratory surrogate signals from PPG and ACC sensing. This RR algorithm is retrospectively evaluated on a controlled respiratory clinical testing dataset from 38 subjects with simultaneously recorded wearable sensor data and a standard capnography monitor as an RR reference. The proposed RR method shows great performance and robustness in determining RR measurements over a wide range of 4-59 brpm with an overall bias of -1.3 brpm, mean absolute error (MAE) of 2.7±1.6 brpm, and a meager outage of 0.3±1.2%, while a standard PPG Smart Fusion method produces a bias of -3.6 brpm, an MAE of 5.5±3.1 brpm, and an outage of 0.7±2.5% for direct comparison. In addition, the proposed algorithm showed no significant differences (p=0.63) in accurately determining RR values in subjects with darker skin tones, while the RR performance of the PPG Smart Fusion method is significantly (P<0.001) affected by the darker skin pigmentation. This study demonstrates a highly accurate RR algorithm for unobtrusive continuous RR monitoring using an armband wearable device.

Respiratory Rate Estimation using PPG: A Deep Learning Approach

Respiratory rate (RR) is an important vital sign marker of health, and it is often neglected due to a lack of unobtrusive sensors for objective and convenient measurement. The respiratory modulations present in simple photoplethysmogram (PPG) have been useful to derive RR using signal processing, waveform fiducial markers, and hand-crafted rules. An end- to-end deep learning approach based on residual network (ResNet) architecture is proposed to estimate RR using PPG. This approach takes time-series PPG data as input, learns the rules through the training process that involved an additional synthetic PPG dataset generated to overcome the insufficient data problem of deep learning, and provides RR estimation as outputs. The inclusion of a synthetic dataset for training improved the performance of the deep learning model by 34%. The final mean absolute error performance of the deep learning approach for RR estimation was 2.5±0.6 brpm using 5-fold cross-validation in two widely used public PPG datasets (n=95) with reliable RR references. The deep learning model achieved comparable performance to that of a classical method, which was also implemented for comparison. With large real-world data and reference ground truth, deep learning can be valuable for RR or other vital sign monitoring using PPG and other physiological signals.

Heart Rate and Oxygen Saturation Monitoring With a New Wearable Wireless Device in the Intensive Care Unit: Pilot Comparison Trial

Background

Continuous cardiac monitoring with wireless sensors is an attractive option for early detection of arrhythmia and conduction disturbances and the prevention of adverse events leading to patient deterioration. We present a new sensor design (SmartCardia), a wearable wireless biosensor patch, for continuous cardiac and oxygen saturation (SpO2) monitoring.

Objective

This study aimed to test the clinical value of a new wireless sensor device (SmartCardia) and its usefulness in monitoring the heart rate (HR) and SpO2 of patients.

Methods

We performed an observational study and monitored the HR and SpO2 of patients admitted to the intensive care unit (ICU). We compared the device under test (SmartCardia) with the ICU-grade monitoring system (Dräger-Healthcare). We defined optimal correlation between the gold standard and the wireless system as <10% difference for HR and <4% difference for SpO2. Data loss and discrepancy between the two systems were critically analyzed.

Results

A total of 58 ICU patients (42 men and 16 women), with a mean age of 71 years (SD 11), were included in this study. A total of 13.49 (SD 5.53) hours per patient were recorded. This represents a total recorded period of 782.3 hours. The mean difference between the HR detected by the SmartCardia patch and the ICU monitor was 5.87 (SD 16.01) beats per minute (bias=–5.66, SD 16.09). For SpO2, the average difference was 3.54% (SD 3.86; bias=2.9, SD 4.36) for interpretable values. SmartCardia’s patch measures SpO2 only under low-to-no activity conditions and otherwise does not report a value. Data loss and noninterpretable values of SpO2 represented 26% (SD 24) of total measurements.

Conclusions

The SmartCardia device demonstrated clinically acceptable accuracy for HR and SpO2 monitoring in ICU patients.